JP2021501601A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501601A5 JP2021501601A5 JP2020542053A JP2020542053A JP2021501601A5 JP 2021501601 A5 JP2021501601 A5 JP 2021501601A5 JP 2020542053 A JP2020542053 A JP 2020542053A JP 2020542053 A JP2020542053 A JP 2020542053A JP 2021501601 A5 JP2021501601 A5 JP 2021501601A5
- Authority
- JP
- Japan
- Prior art keywords
- cornulin
- protein
- seq
- loss
- function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102100032202 Cornulin Human genes 0.000 claims 43
- 101710148705 Cornulin Proteins 0.000 claims 43
- 150000007523 nucleic acids Chemical group 0.000 claims 27
- 108020004707 nucleic acids Proteins 0.000 claims 18
- 102000039446 nucleic acids Human genes 0.000 claims 18
- 150000001413 amino acids Chemical class 0.000 claims 14
- 235000018417 cysteine Nutrition 0.000 claims 13
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 13
- 238000000034 method Methods 0.000 claims 12
- 208000017520 skin disease Diseases 0.000 claims 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 9
- 239000002299 complementary DNA Substances 0.000 claims 9
- 239000000523 sample Substances 0.000 claims 9
- 102000007982 Phosphoproteins Human genes 0.000 claims 7
- 108010089430 Phosphoproteins Proteins 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 235000018102 proteins Nutrition 0.000 claims 7
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 235000001014 amino acid Nutrition 0.000 claims 5
- 230000000295 complement effect Effects 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 108020004705 Codon Proteins 0.000 claims 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 229960003735 brodalumab Drugs 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 231100000221 frame shift mutation induction Toxicity 0.000 claims 1
- 230000037433 frameshift Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 229960005435 ixekizumab Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 229960004540 secukinumab Drugs 0.000 claims 1
- -1 solarene Chemical compound 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229940113082 thymine Drugs 0.000 claims 1
- 229960003824 ustekinumab Drugs 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572958P | 2017-10-16 | 2017-10-16 | |
| US62/572,958 | 2017-10-16 | ||
| PCT/US2018/055995 WO2019079238A1 (en) | 2017-10-16 | 2018-10-16 | CORNULIN VARIANTS (CRNN) AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021501601A JP2021501601A (ja) | 2021-01-21 |
| JP2021501601A5 true JP2021501601A5 (cg-RX-API-DMAC7.html) | 2021-11-25 |
Family
ID=64110144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542053A Withdrawn JP2021501601A (ja) | 2017-10-16 | 2018-10-16 | コルヌリン（ｃｒｎｎ）バリアント及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11098363B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3697807A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021501601A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200065045A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111315765A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018352234A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3079167A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL273671A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020003565A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2020115869A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202002822XA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019079238A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021067740A1 (en) * | 2019-10-03 | 2021-04-08 | Regeneron Pharmaceuticals, Inc. | A crnn loss of function rodent model |
| KR102742136B1 (ko) | 2020-05-29 | 2024-12-11 | 주식회사 엘지에너지솔루션 | 양극 스크랩을 이용한 활물질 재사용 방법 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5294533A (en) | 1988-07-05 | 1994-03-15 | Baylor College Of Medicine | Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria |
| US5135917A (en) | 1990-07-12 | 1992-08-04 | Nova Pharmaceutical Corporation | Interleukin receptor expression inhibiting antisense oligonucleotides |
| US5271941A (en) | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
| US5786138A (en) | 1993-01-29 | 1998-07-28 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Hyperstabilizing antisense nucleic acid binding agents |
| AU693097B2 (en) | 1993-06-04 | 1998-06-25 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Method for treating kaposi's sarcoma with antisense oligonucleotides |
| US5578716A (en) | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
| US5641754A (en) | 1994-01-10 | 1997-06-24 | The Board Of Regents Of The University Of Nebraska | Antisense oligonucleotide compositions for selectively killing cancer cells |
| EP0775204A1 (en) | 1994-08-09 | 1997-05-28 | Novartis AG | Antitumor antisense oligonucleotides |
| US5856103A (en) | 1994-10-07 | 1999-01-05 | Board Of Regents The University Of Texas | Method for selectively ranking sequences for antisense targeting |
| US5994320A (en) | 1995-02-06 | 1999-11-30 | Regents Of The University Of Minnesota | Antisense oligonucleotides and methods for treating central nervous system tumors |
| IT1275862B1 (it) | 1995-03-03 | 1997-10-24 | Consiglio Nazionale Ricerche | Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento |
| US6040296A (en) | 1995-06-07 | 2000-03-21 | East Carolina University | Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation |
| WO1997014709A1 (en) | 1995-10-13 | 1997-04-24 | F. Hoffmann-La Roche Ag | Antisense oligomers |
| JPH11507245A (ja) | 1995-11-21 | 1999-06-29 | アイシーエヌ・ファーマシューティカルズ・インコーポレイテッド | Ｉｌ―８およびｉｌ―８受容体に対するアンチセンスオリゴヌクレオチドによる睡瘍増殖の阻害 |
| AU708535B2 (en) | 1996-02-15 | 1999-08-05 | Cleveland Clinic Foundation, The | RNase L activators and antisense oligonucleotides effective to treat RSV infections |
| US5955590A (en) | 1996-07-15 | 1999-09-21 | Worcester Foundation For Biomedical Research | Conjugates of minor groove DNA binders with antisense oligonucleotides |
| US6046004A (en) | 1997-02-27 | 2000-04-04 | Lorne Park Research, Inc. | Solution hybridization of nucleic acids with antisense probes having modified backbones |
| JPH1142091A (ja) | 1997-07-25 | 1999-02-16 | Toagosei Co Ltd | アンチセンス核酸化合物 |
| US6046319A (en) | 1997-10-22 | 2000-04-04 | University Technologies International, Inc. | Antisense oligodeoxynucleotides regulating expression of TNF-α |
| CA2316182A1 (en) * | 1998-02-09 | 1999-08-12 | Genset S.A. | Cdnas encoding secreted proteins |
| GB9805918D0 (en) * | 1998-03-19 | 1998-05-13 | Nycomed Amersham Plc | Sequencing by hybridisation |
| US6007995A (en) | 1998-06-26 | 1999-12-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of TNFR1 expression |
| US6013522A (en) | 1999-02-23 | 2000-01-11 | Isis Pharmaceuticals Inc. | Antisense inhibition of human Smad1 expression |
| US6025198A (en) | 1999-06-25 | 2000-02-15 | Isis Pharmaceuticals Inc. | Antisense modulation of Ship-2 expression |
| US6033910A (en) | 1999-07-19 | 2000-03-07 | Isis Pharmaceuticals Inc. | Antisense inhibition of MAP kinase kinase 6 expression |
| WO2013176772A1 (en) | 2012-05-25 | 2013-11-28 | The Regents Of The University Of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| LT3138910T (lt) | 2012-12-06 | 2017-11-10 | Sigma-Aldrich Co. Llc | Crispr pagrįstas genomo modifikavimas ir reguliavimas |
| CN106620694B (zh) * | 2016-12-30 | 2019-12-27 | 西安交通大学 | Cornulin作为靶点在制备防治银屑病的药物中的应用 |
-
2018
- 2018-10-16 MX MX2020003565A patent/MX2020003565A/es unknown
- 2018-10-16 US US16/161,331 patent/US11098363B2/en active Active
- 2018-10-16 CA CA3079167A patent/CA3079167A1/en active Pending
- 2018-10-16 SG SG11202002822XA patent/SG11202002822XA/en unknown
- 2018-10-16 EP EP18797344.1A patent/EP3697807A1/en not_active Withdrawn
- 2018-10-16 AU AU2018352234A patent/AU2018352234A1/en not_active Withdrawn
- 2018-10-16 KR KR1020207013082A patent/KR20200065045A/ko not_active Withdrawn
- 2018-10-16 WO PCT/US2018/055995 patent/WO2019079238A1/en not_active Ceased
- 2018-10-16 RU RU2020115869A patent/RU2020115869A/ru unknown
- 2018-10-16 CN CN201880072216.5A patent/CN111315765A/zh not_active Withdrawn
- 2018-10-16 JP JP2020542053A patent/JP2021501601A/ja not_active Withdrawn
-
2020
- 2020-03-29 IL IL273671A patent/IL273671A/en unknown
-
2021
- 2021-07-19 US US17/378,900 patent/US20220017964A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Singh et al. | Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing β-interferon therapy | |
| JP2016516735A5 (cg-RX-API-DMAC7.html) | ||
| JP2014510533A (ja) | サイクリン依存性キナーゼ阻害剤に関連するマーカー | |
| JP2016511406A5 (cg-RX-API-DMAC7.html) | ||
| Wang et al. | Identification of distinct immune cell subsets associated with asymptomatic infection, disease severity, and viral persistence in COVID-19 patients | |
| JP2012512389A5 (cg-RX-API-DMAC7.html) | ||
| Tremlett et al. | Serum proteomics in multiple sclerosis disease progression | |
| EP3347712B1 (en) | Methods of identifying drug-modulated polypeptide targets for degradation | |
| CN109313182B (zh) | 鱼变态反应的抗原 | |
| Meng et al. | Genome-wide expression profiling and mutagenesis studies reveal that lipopolysaccharide responsiveness appears to be absolutely dependent on TLR4 and MD-2 expression and is dependent upon intermolecular ionic interactions | |
| CN110402393A (zh) | 疾病诊断的组合物 | |
| JP2021501601A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2006073195A1 (ja) | 糖尿病の予知・診断方法および糖尿病予知・診断用キット | |
| CN107312861A (zh) | 一种b‑all患者预后风险评估标记物 | |
| Morrissey et al. | The eukaryotic elongation factor eEF1A1 interacts with SAMHD1 | |
| JP2015502137A5 (cg-RX-API-DMAC7.html) | ||
| CN102186976A (zh) | 修饰型生物素结合蛋白 | |
| CN107190071B (zh) | 一种用于检测RhD变异表型的SNP标记 | |
| KR101547307B1 (ko) | 뇌전증 진단용 바이오마커 | |
| Safarikova et al. | Mutational analysis of ACTN4, encoding [alpha]-actinin 4, in patients with focal segmental glomerulosclerosis using HRM method | |
| RU2020115869A (ru) | Варианты корнулина (crnn) и их применение | |
| JP2014527175A (ja) | 精神発達、神経または神経精神障害の処置における臨床的有用性を予測するための方法 | |
| Hebb et al. | Effects of IFN‐B on TRAIL and Decoy Receptor Expression in Different Immune Cell Populations from MS Patients with Distinct Disease Subtypes | |
| Zahoor et al. | Novel mutations identified in EIF2B5 gene in Kashmiri patients as susceptibility factor for multiple sclerosis | |
| US20150065380A1 (en) | Brain somatic mutations associated to epilepsy and uses thereof |